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The abundance and functional orientation of tumor-
infiltrating effector cells has long been observed to pre-
dict for reduced incidence of clinical metastasis and can-
cer-specific death. Using bioinformatics to mine large
breast tumor microarray datasets, we and others have
identified prognostic immune gene signatures, or meta-
genes. Robust evidence indicates that these metagenes
are: 1) positively correlated with distant metastasis-free
survival (DMFS) of patients, 2) comprised of genes that
regulate immune cell-specific biology, and 3) reflective
of the relative abundance of discernible populations of
tumor infiltrating leukocytes. In recent work we have
leveraged the statistical associations between the
immune metagenes and the DMFS of breast cancer
patients to explore the underlying phenotypes that differ
in their ability to potentiate long-term, immune-
mediated tumor rejection. Using a tumor classification
model that combines the prognostic attributes of three
distinct immune metagenes, termed the B/P, T/NK and
M/D metagenes, we have identified molecular subtypes
of breast cancer that either permit or prohibit prognostica-
tion by the immune metagenes. On this basis, we have deli-
neated the phenotypic attributes of breast cancer that
distinguish two novel immunogenic tumor subtypes, which
we have defined as: immune benefit-enabled (IBE) and
immune benefit-disabled (IBD). Phenotypically, IBE tumors
comprise of Basal-like tumors and highly-proliferative
HER2-Enriched and Luminal-B subtypes, while IBD tumors
comprise of Claudin-Low, Luminal-A, and low-proliferative
HER2-Enriched and Luminal-B tumors. Prognostically, IBE
tumors (n = 666) can be stratified by the immune metagene
model into prognostic subgroups with high statistical signif-
icance (P<0.0001,log-rank test), while IBD tumors cannot
(n = 1005, P = 0.3) consistent with the capacity for an
innate anti-tumor immunity against IBE tumors, but not
IBD tumors, that guards against distant metastasis. Further-
more, these observations were independent of adjuvant
treatment, and may owe to differential activation of immu-
nomodulatory pathways. Network analysis revealed that
IBE/IBD differentially-expressed genes (q<0.01) underlie
highly-significant pathway activation scores for TGF-beta
signaling in IBD (p < 0.0001), and Interferon-gamma signal-
ing in IBE (p < 0.0001). Furthermore, 15 of 19 genes com-
prising the previously described Immunologic Constant of
Rejection (Marincola and colleagues) were significantly
overexpressed in IBE tumors (P-value range: 0.05-3.5E-14).
Thus, we conclude that breast tumors can be dichotomized
into two subtypes fundamentally distinct with respect
to their potential for metastasis-protective immune respon-
siveness. These findings indicate new contexts for studying
anti-tumor immunity and oncogenic mechanisms of immu-
nosuppression in breast cancer. Whether IBE and IBD sub-
types represent clinically-relevant contexts for assessing
patient prognosis or evaluating the efficacy of immunother-
apeutic treatments warrants further investigation
(See Figure 1).
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Figure 1 (A-D) The immune metagenes are prognostic of IBE but no IBD breast cancer. (A) Heatmaps of metagene expression levels
(rows) across 1,954 tumors (columns). Key shows color scale of mean centered, log2-transformed gene signal intensities. For each metagene,
tumors are aligned by ascending metagene scores; tertile thresholds are show (33rd and 66th percentiles) for defining low (L), intermediate (I)
and high (H) metagene tertiles. (B) IMM prognostic risk groups are shown. (C, D) IBE and IBD type tumors are shown stratified by IMM
subclasses (FID, WID, PID) in Kaplan-Meier plots of DMFS. The number of tumors (n) in each subclass is shown; the log-rank p-value is reported.
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